Tech Company M&A Transactions
Grail Acquisition
Grail was purchased by Illumina. The transaction became public on 9/21/2020. Illumina disclosed that the acquisition price was $8 billion.
Transaction Overview
Company Name
Acquired By
Announced On
9/21/2020
Transaction Type
M&A
Amount
$8,000,000,000
M&A Terms
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. The agreement has been approved by the Boards of Directors of Illumina and GRAIL.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1525 O'Brien Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Grail's mission is to detect cancer early, when it can be cured.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hans Bishop
Chief Medical Officer
Joshua Ofman
Chief Operating Officer
Matthew Young
President
Harpal Kumar
VP - Bus. Development
Gautam Kollu
VP - General Counsel
Marissa Song
VP - R & D
Alex Aravanis
Browse more venture capital transactions:
Prev: 9/21/2020: Rebelstork venture capital transaction
Next: 9/22/2020: Canexia Health venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are derived from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs